Luxembourg Country Drug Report 2019

Drug-related infectious diseases

Data on drug-related infectious diseases are collected at the national level through the National Retrovirology Laboratory and complemented by the information obtained through the multi-sector national network RELIS (the national monitoring system on drugs and drug addictions, based on self-reports) and specific studies. Luxembourg experienced a human immunodeficiency virus (HIV) outbreak among people who inject drugs (PWID) with a peak of 19 reported cases in 2016. In 2017, there were nine newly diagnosed cases of HIV infection associated with injecting drug use. The outbreak has been linked to, among other factors, an increase in cocaine injecting among marginalised groups. Responses to the outbreak included scaling up prevention and harm reduction services, testing and linkage to HIV treatment.

Prevalence of HIV and HCV antibodies among people who inject drugs in Luxembourg (%)
  Region HCV HIV
Data from 2017.
National 75.8 9.09
Sub-national : :

In 2017, diagnostic testing of 66 PWID from drug treatment centres, needle and syringes programmes, sexually transmitted infection clinics and prisons showed that around 1 in 10 PWID were HIV positive and three quarters were positive for hepatitis C virus (HCV) antibodies.


Luxembourg main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.